Alx Oncology Ownership
| ALXO Stock | USD 1.31 0.15 10.27% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 51.8 M | Current Value 52.7 M | Avarage Shares Outstanding 38 M | Quarterly Volatility 9.2 M |
Alx |
Alx Stock Ownership Analysis
About 95.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.5. Some equities with similar Price to Book (P/B) outperform the market in the long run. Alx Oncology Holdings recorded a loss per share of 2.97. The entity had not issued any dividends in recent years. ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company was founded in 2015 and is headquartered in South San Francisco, California. Alx Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 52 people. For more info on Alx Oncology Holdings please contact Jason Lettmann at 650 466 7125 or go to https://www.alxoncology.com.Alx Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Alx Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Alx Oncology Holdings backward and forwards among themselves. Alx Oncology's institutional investor refers to the entity that pools money to purchase Alx Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Investments Llc | 2024-09-30 | 660.1 K | Privium Fund Management B.v. | 2024-09-30 | 509.1 K | Two Sigma Advisers, Llc | 2024-09-30 | 500.5 K | Qube Research & Technologies | 2024-09-30 | 457.7 K | Cubist Systematic Strategies, Llc | 2024-09-30 | 383.5 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 320.8 K | Northern Trust Corp | 2024-09-30 | 319.7 K | Xtx Topco Ltd | 2024-09-30 | 317.3 K | D. E. Shaw & Co Lp | 2024-09-30 | 290.4 K | Venbio Partners Llc | 2024-09-30 | 9.7 M | Fmr Inc | 2024-09-30 | 5.9 M |
Alx Oncology Holdings Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alx Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alx Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alx Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Alx Oncology Outstanding Bonds
Alx Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Alx Oncology Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Alx bonds can be classified according to their maturity, which is the date when Alx Oncology Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| AMC ENTMT INC Corp BondUS00165AAH14 | View | |
| AMC Networks 425 Corp BondUS00164VAF04 | View | |
| AMC Entertainment Holdings Corp BondUS00165CBA18 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AMC ENTMT HLDGS Corp BondUS00165CAB00 | View | |
| AMC ENTMT HLDGS Corp BondUS00165CAD65 | View | |
| AMC ENTMT HLDGS Corp BondUS00165CAP95 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Pair Trading with Alx Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alx Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alx Oncology will appreciate offsetting losses from the drop in the long position's value.Moving against Alx Stock
| 0.58 | JNJ | Johnson Johnson | PairCorr |
| 0.45 | KRYS | Krystal Biotech | PairCorr |
| 0.45 | PDSB | PDS Biotechnology Corp | PairCorr |
| 0.37 | NKTX | Nkarta Inc | PairCorr |
| 0.31 | INZY | Inozyme Pharma | PairCorr |
The ability to find closely correlated positions to Alx Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alx Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alx Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alx Oncology Holdings to buy it.
The correlation of Alx Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alx Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alx Oncology Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alx Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.